In a study investigating the use of magic mushrooms in Canada, almost 80% of respondents expressed their conviction that psilocybin should be made accessible as a medicinal remedy for patients in distress. Moreover, about two-thirds of these Canadian respondents agreed on the legal accessibility of psilocybin for those who require it.
Aside from advocating for easier access to the substance, a notable 84.8 percent of respondents believe that the public health system should cover the expenses of such treatments. A substantial number of Canadians consider psilocybin as a credible option, especially for managing end-of-life distress.
[toc]
Key Takeaways:
- Inhabitants of Québec, Ontario, Alberta, and British Columbia perceive psilocybin as a legitimate medical option for managing end-of-life existential distress.
- Magic mushrooms are deemed safe for the treatment of existential distress.
- Participants in two double-blind trials reported immediate and long-lasting benefits, with effects enduring six months or more.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their own mortality. It triggers feelings of helplessness, isolation, anxiety, and a loss of purpose and meaning. Patients with life-threatening illnesses are particularly susceptible to this type of distress, potentially leading to thoughts of hastening death or contemplating suicide.
Generally, it is the individuals who are battling terminal diseases or major life changes who frequently experience this kind of distress. It significantly impacts their mental health and overall life quality.
Existential therapy aims to address issues such as anxiety, depression, grief, loneliness, apathy, despair, confusion about identity, feelings of purposelessness and existential fear. Multiple sessions might be required and it may not yield effective results for everyone.
The doubt related to the effectiveness of such therapy is a key reason why many individuals seek out alternative treatments.
The Stance of Health Canada on Psilocybin as a Therapeutic Measure
In the last two decades, preliminary clinical trials have emphasized the potential advantages of psychedelic substances in managing complex mental disorders. Specifically, psilocybin has been identified as a compound that can quickly and effectively mitigate existential distress in patients approaching the end of life.
Recognizing the possible efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments fail, Health Canada revised the Special Access Program in 2022. This revision enables healthcare professionals to request controlled substances for their patients.
Canadian Advocacy for Psilocybin Access
A research presented in the Palliative Care Journal evaluates societal viewpoints on psilocybin-assisted therapy for end-of-life care. The study’s data comprises of:
| Methodology | Engagement of 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of these people had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% regard psilocybin-assisted therapy as a legitimate medical choice for treating end-of-life existential distress. 63.3% opine that psilocybin should be integrated into medical treatment. 84.8% endorse the delivery of this therapy by the public health system. 44.2% believe that healthcare professionals should administer the substance without Health Canada’s supervision. |
These findings align with surveys from Canada, England, and Australia. The researchers stressed that their study is distinctive as it focuses on the usage of psychoactive substances to alleviate existential distress in terminal situations.
Factors Behind Canadian Advocacy for Psilocybin Use
The use of psilocybin for treatment is gaining acceptance among an increasing number of Canadians. This is mainly due to discoveries from esteemed research institutions. The perceived harmlessness of psilocybin mushrooms in relieving existential distress is another influential factor. Subjects across different studies have not reported severe adverse health effects, like multi-organ failure.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin and a low dose as an active placebo control | Immediate and sustained The success of this therapy is largely due to mystical experiences, often characterized by a profound sense of unity and deep emotional revelations, which can last up to six months or more. |
| New York University Trial | 29 patients were randomly selected to either receive psilocybin or the active placebo niacin | The outcome of this study reflected the results of the Johns Hopkins study. Participants who received psilocybin reported psychological relief and a more positive outlook on life and death. |
| BMC Palliative Care | The study involved interviewing nineteen participants, which included 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist. The aim of the study was to understand how professionals in palliative care perceive existential distress and their views on psychedelic therapy as a possible treatment. | Based on the feedback from palliative care professionals, psychedelic-assisted therapy (PAT) seems to hold promise in alleviating existential distress. |
Patient Experiences
Scientific research is not the sole source of evidence supporting the effectiveness of psilocybin. Several patient narratives highlight its potential to improve mental health and overall quality of life.
The Journey of Yokoi
Mio Yokoi, a patient with terminal stage 4 pancreatic cancer, shares her transformative experience during her assisted therapy. She visualizes herself on a raft, surrounded by nature and whimsical creatures. This vision imparts a profound understanding of the universe’s interconnectedness and support, filling her with immense peace and assurance.
Despite receiving conventional mental health support, Yokoi continued to face severe anxiety and distress following her diagnosis. Psilocybin therapy helped her reconnect with her body and provided a tangible sense of love and support, significantly improving her emotional and mental health.
Chrissy’s Tale
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. During the study, she worked full-time as an administrative supervisor in healthcare and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy reported significant reductions in her levels of anxiety, depression, fear of death, hopelessness, and demoralization. When asked about any changes in her religious or spiritual beliefs since her therapy session, she noted that the experiences had infused her beliefs with meaning and substance.
The Experience of Brenda
Brenda, a woman in her sixties, was diagnosed with Stage I colon cancer. She had never previously used hallucinogens and was suffering from Chronic Adjustment Disorder with associated anxiety.
In the course of her therapy, Brenda had two experiences that felt like dying. However, rather than inciting fear, these experiences led her to perceive death as a natural and beautiful part of existence. She credits the therapy for initiating her healing journey from past childhood traumas. The data collected during her treatment reflects this profound transformation. Increased spirituality and a decrease in death anxiety and fear were observed.
Availability of Magic Mushroom Products in Canada
At present, access to psilocybin capsules and other similar products, used for managing existential unease or other mental health disorders, might be limited. Nonetheless, reliable online dispensaries can be a good avenue for obtaining these products when necessary.
| Feature | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some neighboring South American countries. | Discovered in Cambodia, near the Angkor Wat Temple. | Associated with Penis Envy mushrooms, which became popular in the 1970s. |
| Strength | Moderately potent; suitable for first-time users. | Similarly potent; ideal for beginners. | Highly potent; recommended for those with a fair amount of experience. |
| Effects | Creates a mental buzz, slight disorientation, heightened color perception, feelings of euphoria, spiritual experiences, increased creativity, and improved focus. | Results in an energizing and long-lasting high, minor visual changes, enhanced creativity, euphoria, a gentle physical high, fractal images, and happiness. | Leads to intense shamanic and mystical experiences, increased creativity, focus, social awareness, and mood enhancement. |
Using Psilocybin Products to Ease End-of-life Discomfort
Existential or end-of-life distress can significantly affect patients nearing the end of their lives. Conventional treatment methods can sometimes be inadequate, leading to an increase in the Canadian public’s advocacy for easier access to magic mushrooms within the public healthcare system. This growing public interest could
We implore regulatory authorities to recognize the therapeutic value of magic mushrooms. Obtain your psychedelics and mushroom delivery from Microdosing Mushrooms Canada.
Frequently Asked Questions
What should patients expect when participating in Psilocybin-Assisted Therapy?
The patient’s experience with Psychedelic-assisted therapy (PAT) can differ significantly, and diligent preparation and adherence to specific procedures are crucial for a positive outcome. Patients must undergo thorough screening and mental preparation before ingesting the substance.
- Preparation Phase: Patients undergo an extensive evaluation. The therapist discusses the patient’s goals and expectations to set the session’s intentions. The therapist educates the patient about the process’s impact and what to expect during the session.
- Therapy Session: Patients receive a controlled dose of the substance in a calm, distraction-free environment to promote relaxation and self-reflection. The therapist provides ongoing support and guidance during this time.
- Post-Session Integration Therapy: This therapy helps the patient interpret and process their experiences. Follow-up sessions offer continued support and counselling to reinforce the insights and changes achieved during therapy.
How does psilocybin affect the brains of distressed patients?
It connects with the brain by latching on to serotonin receptors, particularly the 5-HT2A receptor. This interaction can lead to alterations in perception, mood, and cognition, resulting in substantial shifts in consciousness, emotional insights, and new viewpoints.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not applicable to everyone. Patients with specific mental health conditions or existential distress must undergo comprehensive screening to rule out those with a history of psychosis.
Related Articles:
